Astellas Pharma (FRA:YPHA) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:YPHA Astellas Pharma Inc FRA:YPHA
82 GF Score
Price €11.00
GF Value €11.62
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Astellas Pharma Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:YPHA
82GF Score
Astellas Pharma Inc FRA:YPHA
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Astellas Pharma (FRA:YPHA) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued. The current stock price of €11.00 is trading 5.3% below its estimated GF Value™ of €11.62. GuruFocus considers Astellas Pharma to be Fairly Valued.

Key valuation signals for FRA:YPHA:

  • Short Ratio:
  • GF Value™: €11.62 vs. price of €11.00 (5.3% below fair value)
  • GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the FRA:YPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
82GF Score

Get the complete analysis for FRA:YPHA

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.00
Price
€11.62
GF Value